CLARITY: Assessment of VenetoCLAx (ABT-199) in combination with IbRutInib in relapsed/refracTory Chronic LymphocYtic Leukaemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLARITY
- 02 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2017 Initial results presented at the 22nd Congress of the European Haematology Association.
- 11 Mar 2016 Planned End Date changed from 1 Sep 2017 to 1 Dec 2021 as reported by ISRCTN: Current Controlled Trials.